ONO-7912 Phase I Study A multicenter, open-label, uncontrolled study in pancreatic cancer (ONO-7912-01)
Latest Information Update: 13 Sep 2022
At a glance
- Drugs Devimistat (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Adenocarcinoma; Pancreatic ductal carcinoma
- Focus Adverse reactions
- Sponsors Ono Pharmaceutical
Most Recent Events
- 12 Sep 2022 Status changed from recruiting to discontinued.
- 20 Oct 2020 Status changed from not yet recruiting to recruiting, according to a Rafael Pharmaceuticals media release.
- 19 Aug 2020 New trial record